Borderline-resectable Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: upfront Surgery or Neoadjuvant Chemotherapy?

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Undifferentiated carcinoma with osteoclast-like giant cells (UDC-OGC) of the pancreas is an extremely rare entity, thus an obvious discrepancy regarding their treatment approach exists in the current literature. A 52-year female patient with a two-weeks history of jaundice was diagnosed as borderline-resectable pancreatic mass located in the uncinate process of a size of 5×4 cm. Pancreaticoduodenectomy (PD) with partial portal vein resection was successfully performed following neoadjuvant chemotherapy (NACT). The pathology was interpreted as UDC-OGC without lymph node involvement. Considering their aggressive behavior, NACT followed by surgery seems to be a good option in case of borderline-resectable UDC-OGC.

Cite

CITATION STYLE

APA

Sozutek, A., & Aktas, E. (2022). Borderline-resectable Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: upfront Surgery or Neoadjuvant Chemotherapy? Journal of the College of Physicians and Surgeons Pakistan, 32(7), 934–937. https://doi.org/10.29271/jcpsp.2022.07.934

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free